[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Ontachi Y, Asakura H, Omote M, Yoshida T, Matsui O, Nakao S: Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid. Haematologica; 2005 Nov;90 Suppl:ECR29
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kasabach-Merritt syndrome associated with giant liver hemangioma: the effect of combined therapy with danaparoid sodium and tranexamic acid.
  • A 39-year-old woman with an enlarging giant liver hemangioma was diagnosed as having KMS with DIC.
  • To control the hemorrhagic diathesis, we commenced combination therapy for DIC with danaparoid (1,250 Ux2/day, intravenously (IV)) and tranexamic acid (0.5 g x 3/day, peros (PO).
  • Rapid improvement of the bleeding tendency and coagulopathy occurred in response to this treatment - that is, DIC was controlled without removing the giant hemangioma.
  • The therapy did not restrict the behavior of the patient by continuous drip and angiography could be performed without bleeding.
  • Such therapy may be beneficial in chronic DIC with activation of fibrinolysis.
  • [MeSH-major] Antifibrinolytic Agents / therapeutic use. Chondroitin Sulfates / therapeutic use. Dermatan Sulfate / therapeutic use. Disseminated Intravascular Coagulation / etiology. Hemangioma / complications. Hemorrhagic Disorders / etiology. Heparitin Sulfate / therapeutic use. Liver Neoplasms / complications. Tranexamic Acid / therapeutic use
  • [MeSH-minor] Adult. Blood Proteins / analysis. Drug Therapy, Combination. Female. Hepatic Artery / surgery. Humans. Ligation. Syndrome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266920.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antifibrinolytic Agents; 0 / Blood Proteins; 24967-94-0 / Dermatan Sulfate; 6T84R30KC1 / Tranexamic Acid; 83513-48-8 / danaproid; 9007-28-7 / Chondroitin Sulfates; 9050-30-0 / Heparitin Sulfate
  •  go-up   go-down


2. Raynaud JJ, Béchade D, Desrame J, Algayres JP: [Corticotherapy and giant hemangioma of the liver. Return to the normal values of cytokines]. Gastroenterol Clin Biol; 2006 Jun-Jul;30(6-7):907-9
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Corticotherapy and giant hemangioma of the liver. Return to the normal values of cytokines].
  • [Transliterated title] Corticothérapie et hémangiome géant du foie. Effets bénéfiques sur les symptômes et normalisation des cytokines.
  • We report the case of a 36 year-old woman presenting with a giant liver hemangioma revealed by febrile hepatomegaly and weight loss.
  • Eight weeks of corticosteroid treatment (prednisone 40 mg/d) resulted in disappearance of symptoms after 48 hours and biological anomalies after 6 weeks.
  • Clinical and radiological follow-up, for respectively 36 and 24 months, did not show any relapse of symptoms or evolution of the hemangioma.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Cytokines / blood. Glucocorticoids / therapeutic use. Hemangioma / drug therapy. Liver Neoplasms / drug therapy. Prednisone / therapeutic use
  • [MeSH-minor] Adult. Biopsy. Female. Humans. Interleukin-1 / blood. Interleukin-6 / blood. Liver / pathology. Magnetic Resonance Imaging. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Tumor Necrosis Factor-alpha / analysis

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885878.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cytokines; 0 / Glucocorticoids; 0 / Interleukin-1; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; VB0R961HZT / Prednisone
  •  go-up   go-down


3. Pascual-Castroviejo I, Pascual-Pascual SI, Rafia S, Viaño J: [Hemangiomas, and cutaneous and intracranial vascular deformations (Pascual-Castroviejo syndrome tipe II ). A case report]. Rev Neurol; 2002 Dec 1-15;35(11):1034-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hemangiomas, and cutaneous and intracranial vascular deformations (Pascual-Castroviejo syndrome tipe II ). A case report].
  • [Transliterated title] Hemangiomas y malformaciones vasculares cutáneas e intracraneales (sindrome de Pascual-Castroviejo tipo II). Presentacion de un caso.
  • OBJECTIVE: To present a case with several cutaneous hemangiomas associated with intracranial hemangiomas and possibly with an intrahepatic hemangioma.
  • CASE REPORT: A boy, 17 months old, showing several cutaneous hemangiomas and epileptic seizures resisting to antiepileptic medication, who also presented psychomotor retardation.
  • The study by angiographic magnetic resonance (AMR ) revealed the presence of three small intracranial angiomas and possibly a hepatic hemangioma.
  • The seizures were controlled with antiepileptic medication.
  • CONCLUSION: This case shows the association of the cutaneous hemangiomas and the subjacent vascular alterations also hemangiomas in this patient which are included in the most frequent neurocutaneous disease, which is known as Pascual Castroviejo syndrome.
  • [MeSH-major] Brain Neoplasms / pathology. Hemangioma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Anticonvulsants / therapeutic use. Humans. Infant. Liver Neoplasms / pathology. Magnetic Resonance Angiography. Male. Psychomotor Disorders. Seizures / drug therapy. Syndrome

  • Genetic Alliance. consumer health - Pascual Castroviejo syndrome.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12497310.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


Advertisement
4. Farruggia P, Alaggio R, Cardella F, Tropia S, Trizzino A, Ferrara F, D'Angelo P: Focal nodular hyperplasia of the liver: an unusual association with diabetes mellitus in a child and review of literature. Ital J Pediatr; 2010;36:41
MedlinePlus Health Information. consumer health - Diabetes Type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal nodular hyperplasia of the liver: an unusual association with diabetes mellitus in a child and review of literature.
  • Hepatic hemangioma, adenoma and focal nodular hyperplasia are the most frequent benign lesions of the liver, but they are all infrequent among pediatric population.
  • The reports of focal nodular hyperplasia in children have recently increased in number, with many cases associated to drug intake, particularly to chemotherapy.
  • [MeSH-major] Diabetes Mellitus, Type 1 / complications. Focal Nodular Hyperplasia / complications
  • [MeSH-minor] Biopsy. Child. Diagnosis, Differential. Follow-Up Studies. Hepatectomy / methods. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Diabetes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1441-54 [10584697.001]
  • [Cites] J Hepatol. 2008 Jul;49(1):61-71 [18466996.001]
  • [Cites] Am J Gastroenterol. 2002 Sep;97(9):2371-3 [12358258.001]
  • [Cites] J Hepatol. 2008 Jan;48(1):163-70 [17997499.001]
  • [Cites] Hepatology. 2006 Jul;44(1):7-14 [16799965.001]
  • [Cites] Pediatr Radiol. 2005 Dec;35(12):1234-9 [16052333.001]
  • [Cites] Arch Pathol Lab Med. 1999 Sep;123(9):846-9 [10458838.001]
  • [Cites] HPB Surg. 1992 Apr;5(3):171-6; discussion 176-80 [1324705.001]
  • [Cites] J Surg Oncol. 1986 Oct;33(2):129-35 [3762186.001]
  • [Cites] Gastroenterol Jpn. 1984 Oct;19(5):419-23 [6083895.001]
  • [Cites] Zentralbl Allg Pathol. 1983;127(1-2):135-43 [6858421.001]
  • [Cites] Am J Med. 1976 Dec;61(6):871-7 [188336.001]
  • [Cites] Acta Pathol Microbiol Scand A. 1975 Nov;83(6):615-22 [171910.001]
  • [Cites] J Hepatol. 2004 Apr;40(4):660-8 [15030983.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):651-9 [12612904.001]
  • [Cites] Gut. 2002 Jun;50(6):877-80 [12010893.001]
  • (PMID = 20504362.001).
  • [ISSN] 1824-7288
  • [Journal-full-title] Italian journal of pediatrics
  • [ISO-abbreviation] Ital J Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2883986
  •  go-up   go-down


5. Muthamilselvan S, Vinoth PN, Vilvanathan V, Ninan B, Amboiram P, Sai V, Anand V, Scott JX: Hepatic haemangioma of infancy: role of propranolol. Ann Trop Paediatr; 2010;30(4):335-8
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic haemangioma of infancy: role of propranolol.
  • A newborn girl with a haemangioma of the liver failed to respond to cortico-steroid therapy.
  • Ultrasonic evidence of the haemangioma disappeared after 2 months of treatment with propranolol.
  • Propranolol, a non-selective beta-blocker, is a promising therapy in the management of haemangiomas.
  • [MeSH-major] Adrenergic beta-Antagonists / therapeutic use. Hemangioma / drug therapy. Infant, Premature, Diseases / drug therapy. Liver Neoplasms / drug therapy. Propranolol / therapeutic use
  • [MeSH-minor] Female. Humans. Infant, Low Birth Weight. Infant, Newborn. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Premature Babies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21118629.001).
  • [ISSN] 1465-3281
  • [Journal-full-title] Annals of tropical paediatrics
  • [ISO-abbreviation] Ann Trop Paediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenergic beta-Antagonists; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


6. Niemelä M, Mäenpää H, Salven P, Summanen P, Poussa K, Laatikainen L, Jääskeläinen J, Joensuu H: Interferon alpha-2a therapy in 18 hemangioblastomas. Clin Cancer Res; 2001 Mar;7(3):510-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon alpha-2a therapy in 18 hemangioblastomas.
  • Multiple but thus far asymptomatic HBs pose a therapeutic problem.
  • IFN-alpha-2a has antiangiogenic activity with an especially favorable effect on life-threatening hemangiomas of the liver in children.
  • This is the first study to assess the efficacy of IFN-alpha-2a in treatment of asymptomatic HBs of the CNS and retina.
  • Four patients (three with VHL) with a combined total of 15 HBs of the CNS, 3 HBs of the retina, and 14 renal and 2 pancreatic cysts were treated with s.c.
  • IFN-alpha-2a for 12 months at 3 x 10(6) IU, 3 times/week.
  • No de novo HBs were detected during the therapy, but one appeared 9 months after cessation of IFN-alpha-2a therapy.
  • HBs of the CNS did not shrink markedly during the therapy.
  • However, the therapy did not prevent visceral cysts from growing.
  • The systemic response was also monitored by measurement of serum levels of vascular endothelial growth factor and erythropoietin, which remained essentially unchanged during the treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Hemangioblastoma / drug therapy. Interferon-alpha / therapeutic use. Retinal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Endothelial Growth Factors / blood. Erythropoietin / blood. Female. Humans. Lymphokines / blood. Male. Middle Aged. Recombinant Proteins. Time Factors. Treatment Outcome. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11297241.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Endothelial Growth Factors; 0 / Interferon-alpha; 0 / Lymphokines; 0 / Recombinant Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 11096-26-7 / Erythropoietin; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


7. Mason KP, Koka BV, Eldredge EA, Fishman SJ, Burrows PE: Perioperative considerations in a hypothyroid infant with hepatic haemangioma. Paediatr Anaesth; 2001 Mar;11(2):228-32
Hazardous Substances Data Bank. LIOTHYRONINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perioperative considerations in a hypothyroid infant with hepatic haemangioma.
  • Hepatic haemangiomas in infants are rare.
  • An infant with both a hepatic haemangioma and a severe hypothyroid condition, unresponsive to conventional thyroxine therapy, will be described.
  • This case presented here is the perioperative management of a critically ill infant who had myocardial depression secondary to hypothyroidism and a hepatic haemangioma that required embolization.
  • To our knowledge, this is the first published report describing intravenous triiodothyronine as a therapeutic modality to stabilize a hypothyroid infant prior to undergoing a general anaesthetic.
  • [MeSH-major] Congenital Hypothyroidism. Hemangioma / surgery. Liver Neoplasms / surgery. Preoperative Care
  • [MeSH-minor] Anesthesia, General. Decompression, Surgical. Embolization, Therapeutic. Humans. Hypothyroidism / complications. Hypothyroidism / drug therapy. Infant. Infusions, Intravenous. Laparotomy. Male. Triiodothyronine / administration & dosage

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11240884.001).
  • [ISSN] 1155-5645
  • [Journal-full-title] Paediatric anaesthesia
  • [ISO-abbreviation] Paediatr Anaesth
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 06LU7C9H1V / Triiodothyronine
  •  go-up   go-down


8. Ocama P, Katwere M, Piloya T, Feld J, Opio KC, Kambugu A, Katabira E, Thomas D, Colebunders R, Ronald A: The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr Health Sci; 2008 Mar;8(1):8-12
Hazardous Substances Data Bank. ISONIAZID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
  • BACKGROUND: Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections.
  • OBJECTIVE: To describe the spectrum of liver diseases in HIV-infected patients attending an HIV clinic in Kampala, Uganda.
  • METHOD: Consecutive patients presenting with jaundice, right upper quadrant pain with fever or malaise, ascites and/or tender hepatomegaly were recruited and underwent investigations to evaluate the cause of their liver disease.
  • Although 14 (61%) patients with drug-induced liver disease presented with jaundice, all recovered with drug discontinuation.
  • Probable granulomatous hepatitis due to tuberculosis was diagnosed in 7 (9%) patients and all responded to anti-TB therapy.
  • Other diagnoses included alcoholic liver disease, AIDS cholangiopathy, hepatocellular carcinoma, schistosomiasis, haemangioma and hepatic adenoma.
  • Twelve (16%) patients died during follow-up of which 7 (9%) died because of liver disease.
  • CONCLUSION: Drug history, liver enzyme studies, ultrasound, and hepatitis B and C investigations identified the probable etiology in 60 (78%) of 77 patients with HIV infection presenting with symptoms and/or signs of liver disease.
  • [MeSH-major] Anti-HIV Agents / adverse effects. Antitubercular Agents / adverse effects. HIV Infections / complications. HIV Infections / drug therapy. Isoniazid / adverse effects. Liver Diseases / epidemiology. Nevirapine / adverse effects. Reverse Transcriptase Inhibitors / adverse effects
  • [MeSH-minor] Comorbidity. Drug-Induced Liver Injury. Female. Follow-Up Studies. Humans. Immunocompromised Host. Incidence. Liver Neoplasms / epidemiology. Male. Prevalence. Time Factors. Treatment Outcome. Tuberculosis / drug therapy. Tuberculosis / epidemiology. Uganda

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • Hazardous Substances Data Bank. NEVIRAPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2000 Jan 5;283(1):74-80 [10632283.001]
  • [Cites] J Int Assoc Physicians AIDS Care (Chic). 2007 Jun;6(2):83-6 [17537997.001]
  • [Cites] Med Sci Monit. 2001 Jul-Aug;7(4):729-36 [11433202.001]
  • [Cites] East Afr Med J. 2002 Feb;79(2):68-72 [12380879.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S80-9 [14986279.001]
  • [Cites] Clin Infect Dis. 2004 Aug 15;39(4):488-96 [15356811.001]
  • [Cites] J Med Virol. 2005 Feb;75(2):209-12 [15602740.001]
  • [Cites] East Afr Med J. 2005 Apr;82(4):170-2 [16122083.001]
  • [Cites] Ann Hepatol. 2005 Jul-Sep;4(3):188-91 [16177658.001]
  • [Cites] J Antimicrob Chemother. 2005 Dec;56(6):1087-93 [16269552.001]
  • [Cites] Antivir Ther. 2005;10(8):953-65 [16430201.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5005-9 [17075119.001]
  • [Cites] World J Gastroenterol. 2006 Nov 14;12(42):6879-83 [17106941.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Nov;6(11):1553-8 [17134360.001]
  • [Cites] AIDS Rev. 2007 Jan-Mar;9(1):40-53 [17474312.001]
  • [Cites] East Afr Med J. 2000 Jan;77(1):13-5 [10944831.001]
  • (PMID = 19357726.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antitubercular Agents; 0 / Reverse Transcriptase Inhibitors; 99DK7FVK1H / Nevirapine; V83O1VOZ8L / Isoniazid
  • [Other-IDs] NLM/ PMC2408539
  •  go-up   go-down


9. Hashimoto M, Sugawara M, Ishiyama K, Sato T, Yamamoto Y, Nanjo H: Reduction in the size of a hepatic haemangioma after chemotherapy. Liver Int; 2008 Aug;28(7):1043-4
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction in the size of a hepatic haemangioma after chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endodermal Sinus Tumor / drug therapy. Hemangioma / drug therapy. Liver Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adult. Bleomycin / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Etoposide / therapeutic use. Female. Humans. Hysterectomy. Magnetic Resonance Imaging. Neoplasms, Multiple Primary. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783545.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; BEP protocol
  •  go-up   go-down


10. Biecker E, Fischer HP, Strunk H, Sauerbruch T: Benign hepatic tumours. Z Gastroenterol; 2003 Feb;41(2):191-200
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign hepatic tumours.
  • Benign hepatic tumours include a broad spectrum of regenerative and true neoplastic processes.
  • Due to advances in imaging procedures like MRI, Cf-scan and ultrasound as well as progress in immunohistochemistry, the appropriate diagnosis is made ina high percentage of patients without laparotomy and resection.
  • Most important in clinical practice is the differential diagnosis of focal nodular hyperplasia and hepatocellular adenoma because of the risk of rupture and bleeding in the latter.
  • Cavernous haemangioma, the most common benign hepatic tumour, rarely needs treatment.
  • The diagnosis of nodular regenerative hyperplasia is often missed and patients present with secondary complications and signs of portal hypertension that necessitate treatment.
  • The main problem in angiomyolipoma is to distinguish it from malignant processes which do require treatment.
  • Therapeutic options are drug therapy or surgical resection.
  • Benign haemangioendothelioma of the infant is rare but may cause life-threatening complications.
  • [MeSH-major] Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / pathology. Adult. Aged. Diagnostic Imaging. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / pathology. Granuloma, Plasma Cell / diagnosis. Granuloma, Plasma Cell / pathology. Hemangioendothelioma / diagnosis. Hemangioendothelioma / pathology. Hemangioma, Cavernous / diagnosis. Hemangioma, Cavernous / pathology. Humans. Infant. Liver / pathology. Liver Regeneration / physiology. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12650132.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 138
  •  go-up   go-down


11. Chan KL, Tang MH, Tse HY, Tang RY, Lam HS, Lee CP, Tam PK: Factors affecting outcomes of prenatally-diagnosed tumours. Prenat Diagn; 2002 May;22(5):437-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Medical records of all fetuses referred to our institutions with antenatally-diagnosed tumours were reviewed for the type and location of the tumours, results of treatment and/or causes of death.
  • RESULTS: From January 1994 to May 2001, there were 15 fetuses with antenatally- diagnosed tumours: mesoblastic nephroma (MN) (n=2); neuroblastoma (NB) (n=2); cystic hygroma (CH) (n=3); intracranial germ cell tumour (IGCT) (n=2); sacrococcygeal teratoma (SCT) (n=3) and haemangioma (liver, n=2; limb, n=1).
  • One baby had cardiac failure resulting from a lower limb haemangioma and needed drug therapy.
  • All solid tumours (MN, NB, SCT) of the live births had no recurrence after surgery with or without adjuvant chemotherapy.
  • Solid tumours are relatively benign.
  • [MeSH-minor] Adult. Female. Gestational Age. Humans. Pregnancy. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 John Wiley & Sons, Ltd.
  • (PMID = 12001204.001).
  • [ISSN] 0197-3851
  • [Journal-full-title] Prenatal diagnosis
  • [ISO-abbreviation] Prenat. Diagn.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Zeng Q, Li Y, Chen Y, Ouyang Y, He X, Zhang H: Gigantic cavernous hemangioma of the liver treated by intra-arterial embolization with pingyangmycin-lipiodol emulsion: a multi-center study. Cardiovasc Intervent Radiol; 2004 Sep-Oct;27(5):481-5
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gigantic cavernous hemangioma of the liver treated by intra-arterial embolization with pingyangmycin-lipiodol emulsion: a multi-center study.
  • PURPOSE: To evaluate the therapeutic effect and safety of pingyangmycin-lipiodol emulsion (PLE) intra-arterial embolization for treating gigantic cavernous hemangioma of the liver (CHL).
  • A total of 98 patients with CHL were embolized with PLE via the hepatic artery.
  • The therapeutic effects including changes in tumor diameter, symptomatic improvement and occurrence of complications were evaluated for a period of 12 months after the procedure.
  • RESULTS: The tumor diameters decreased significantly from 9.7 +/- 2.3 cm to 5.6 +/- 1.6 cm 6 months after the treatment ( P < 0.01), and then to 3.0 +/- 1.2 cm at 12 months ( P < 0.01).
  • Transient impairment of liver function was found in 77 cases after embolization, 69 cases of which returned to normal in 2 weeks, and the other eight cases of which recovered 1 month later.
  • Persistent pain in the hepatic region was found in two cases, and these two patients resorted to surgery eventually.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / analogs & derivatives. Embolization, Therapeutic. Hemangioma, Cavernous / therapy. Iodized Oil / therapeutic use. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aspartate Aminotransferases / metabolism. Bilirubin / metabolism. Biomarkers, Tumor / blood. China. Emulsions. Female. Hepatic Artery / drug effects. Hepatic Artery / pathology. Hepatic Artery / surgery. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome. gamma-Glutamyltransferase / metabolism

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15383851.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Emulsions; 11056-06-7 / Bleomycin; 11116-32-8 / bleomycetin; 8001-40-9 / Iodized Oil; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


13. Strzelczyk J, Bialkowska J, Loba J, Jablkowski M: Rapid growth of liver hemangioma following interferon treatment for hepatitis C in a young woman. Hepatogastroenterology; 2004 Jul-Aug;51(58):1151-3
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid growth of liver hemangioma following interferon treatment for hepatitis C in a young woman.
  • Liver hemangioma is the most common benign liver tumor.
  • Giant hemangiomas can grow and give various clinical symptoms.
  • We describe a case of rapid growth of liver hemangioma in a seventeen-year-old girl.
  • Ultrasound scan and computed tomography confirmed the clinical picture, suggesting giant liver hemangioma.
  • During surgery large cavernous hemangioma deeply penetrating into normal liver parenchyma was found.
  • In view of recent hepatitis C infection the resection procedure (left extended hemihepatectomy) was assessed as being dangerous for the patient's life.
  • Ligation of the left branches of hepatic artery and portal vein reducing tumor blood supply was performed.
  • The postoperative period was uneventful; the hemangioma in the left lobe had shrunk.
  • Ultrasound and CT scans performed one and two years after surgery showed that the size of the hemangioma remained stable and the patient was asymptomatic.
  • In this described case three potential factors stimulating the growth of hemangioma (puberty, hepatitis C infection and interferon treatment) are discussed.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hemangioma, Cavernous / pathology. Hepatitis C / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / pathology
  • [MeSH-minor] Adolescent. Cell Division. Female. Hepatic Artery. Humans. Ligation. Recombinant Proteins. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15239265.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


14. Bessho K, Etani Y, Ichimori H, Miyoshi Y, Namba N, Yoneda A, Ooue T, Chihara T, Morii E, Aoki T, Murakami M, Mushiake S, Ozono K: Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism. Eur J Pediatr; 2010 Feb;169(2):215-21
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased type 3 iodothyronine deiodinase activity in a regrown hepatic hemangioma with consumptive hypothyroidism.
  • INTRODUCTION: Infantile hepatic hemangioma with consumptive hypothyroidism is a rare condition.
  • CASE REPORT: A 4-month-old girl presented with diffuse hepatic hemangiomas during treatment of congenital hypothyroidism.
  • Serum reverse triiodothyronine was elevated, and her hypothyroidism improved concomitant with involution of the hemangioma following prednisolone and interferon-alpha administration.
  • At 20 months of age, 7 months after discontinuing prednisolone and interferon-alpha, a focal hemangioma regrew from one of the previous lesions and was surgically resected.
  • The expression and activity of type 3 iodothyronine deiodinase (D3) were elevated in the resected tumor tissue compared with placenta.
  • DISCUSSION: Here, we describe a patient with consumptive hypothyroidism and diffuse infantile hepatic hemangiomas, one of which regrew after involution following pharmacotherapy.
  • CONCLUSION: It is important to identify infantile hepatic hemangioma in patients with hypothyroidism refractory to hormone replacement therapy, who have low free triiodothyronine despite high thyrotropin and normal free thyroxine levels, and long-term follow-up will be needed for these patients.
  • [MeSH-major] Hemangioma / enzymology. Hypothyroidism / complications. Iodide Peroxidase / metabolism. Liver Neoplasms / enzymology
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Follow-Up Studies. Gene Expression Regulation, Neoplastic. Humans. Infant. Liver / metabolism. Liver / pathology. Magnetic Resonance Imaging. Polymerase Chain Reaction. RNA, Neoplasm / genetics. Time Factors

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Hypothyroidism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Int. 2008 Aug;28(7):1043-4 [18783545.001]
  • [Cites] Paediatr Anaesth. 2001 Mar;11(2):228-32 [11240884.001]
  • [Cites] J Pediatr Endocrinol Metab. 2008 Jul;21(7):701-3 [18780606.001]
  • [Cites] Arch Dermatol. 2001 May;137(5):559-70 [11346333.001]
  • [Cites] Pediatrics. 1970 Jan;45(1):71-6 [5410252.001]
  • [Cites] J Pediatr Surg. 2007 Jan;42(1):62-7; discussion 67-8 [17208542.001]
  • [Cites] J Pediatr. 2001 Jun;138(6):932-5 [11391345.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):1021-4 [16544297.001]
  • [Cites] Pediatrics. 2003 Dec;112(6 Pt 1):1424-6 [14654623.001]
  • [Cites] Pediatrics. 2000 Jan;105(1 Pt 1):117-20 [10617714.001]
  • [Cites] J Perinatol. 2001 Dec;21(8):568-70 [11774023.001]
  • [Cites] Horm Res. 2005;63(2):86-9 [15711094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19097-102 [16365311.001]
  • [Cites] Eur J Pediatr. 1996 May;155(5):423-4 [8741047.001]
  • [Cites] J Pediatr Surg. 2006 Oct;41(10):1783-5 [17011291.001]
  • [Cites] J Pediatr Surg. 1978 Apr;13(2):155-62 [77324.001]
  • [Cites] J Pediatr Surg. 1996 Nov;31(11):1563-7 [8943124.001]
  • [Cites] Mol Cell Endocrinol. 1999 Jan 25;147(1-2):49-56 [10195691.001]
  • [Cites] Hum Pathol. 2004 Feb;35(2):200-9 [14991538.001]
  • [Cites] J Pediatr Surg. 1999 Jan;34(1):98-105; discussion 105-6 [10022152.001]
  • [Cites] N Engl J Med. 2000 Jul 20;343(3):185-9 [10900278.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1705 [17914938.001]
  • [Cites] Pediatr Pathol. 1988;8(6):625-31 [2469076.001]
  • [Cites] Pediatr Radiol. 1983;13(5):297-300 [6622093.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1997 Mar;24(3):348-51 [9138183.001]
  • [Cites] AJR Am J Roentgenol. 2004 Mar;182(3):785-95 [14975986.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3117-28 [15240580.001]
  • [Cites] Curr Opin Pediatr. 2008 Apr;20(2):213-5 [18332720.001]
  • [Cites] Pediatr Hematol Oncol. 2006 Dec;23 (8):639-47 [17065140.001]
  • (PMID = 19548001.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Neoplasm; EC 1.11.1.- / iodothyronine deiodinase type III; EC 1.11.1.8 / Iodide Peroxidase
  •  go-up   go-down


15. Takahashi A, Ogawa C, Kanazawa T, Watanabe H, Suzuki M, Suzuki N, Tsuchida Y, Morikawa A, Kuwano H: Remission induced by interferon alfa in a patient with massive osteolysis and extension of lymph-hemangiomatosis: a severe case of Gorham-Stout syndrome. J Pediatr Surg; 2005 Mar;40(3):E47-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of massive osteolysis with lymphangioma and/or hemangioma (Gorham-Stout syndrome) has been controversial.
  • The authors report on a patient with multiple massive osteolyses and extensive lymph-hemangiomatosis whose lesions were reduced by interferon alfa therapy.
  • There were also hemangiomas in the liver and spleen, a tumor lesion in the left lower chest wall, and hemangiomatous change on the skin surface of the left back.
  • After steroid pulse therapy, pericardial effusion disappeared.
  • During these treatments, the 7th to 10th ribs disappeared from the x-ray and scoliosis developed.
  • One month later, a cloudy fluid collection in the right lung was found on computed tomography.
  • Interferon alfa and steroid pulse therapy were started.
  • Steroids were also reduced and maintained at 5 mg/d of predonine.
  • Ten months later, hemangioma in the back disappeared, and the 7th to 10th ribs, which had disappeared, reappeared.
  • The interferon alfa therapy was stopped 14 months after it was administered.
  • At this time, computed tomography shows regression of the hemangiomatous lesion in the back.
  • Interferon alfa with or without steroid therapy should be a choice for patients with extension lesions.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Interferon-alpha / therapeutic use. Osteolysis, Essential / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Antineoplastic Agents / therapeutic use. Child, Preschool. Chylothorax / etiology. Drug Therapy, Combination. Female. Femur / pathology. Hemangioma / drug therapy. Humans. Liver Neoplasms / drug therapy. Lymphangioma / complications. Lymphangioma / drug therapy. Neoplasms, Multiple Primary / drug therapy. Picibanil / therapeutic use. Pleural Effusion / etiology. Pulmonary Atelectasis / etiology. Remission Induction. Ribs / pathology. Scoliosis / etiology. Skin Neoplasms / drug therapy. Spine / pathology. Splenic Neoplasms / drug therapy. Syndrome. Thoracic Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793714.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 39325-01-4 / Picibanil
  •  go-up   go-down


16. Isaacs H Jr: Fetal and neonatal hepatic tumors. J Pediatr Surg; 2007 Nov;42(11):1797-803
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal and neonatal hepatic tumors.
  • BACKGROUND/PURPOSE: Although hepatic tumors are uncommon in the perinatal period they are associated with significant morbidity and mortality in affected patients.
  • The purpose of this review is to focus on the fetus and neonate in an attempt to determine the various ways liver tumors differ clinically and pathologically from those found in the older child and adult and to show that certain types of tumors have a better prognosis than others.
  • METHODS: The author conducted a retrospective review of perinatal hepatic tumors reported in the literature and of patients treated and followed up at Children's Hospital San Diego and Children's Hospital Los Angeles.
  • Discussion of the differential diagnosis and pathologic findings of hepatic tumors in the fetus and neonate are described elsewhere and will not be discussed here in detail (Perspect Pediatr Pathol 1978;4:217; Weinberg AG, Finegold MJ.
  • Primary hepatic tumors in childhood.
  • Liver tumors. In: Isaacs H Jr, editor.
  • Liver tumors. In: Isaacs H Jr, editor.
  • RESULTS: One hundred ninety-four fetuses and neonates presented with hepatic tumors diagnosed prenatally (n = 56) and in the neonatal period (n = 138).
  • The study consisted of 3 main tumors: hemangioma (117 cases, 60.3%), mesenchymal hamartoma (45 cases, 23.2%), and hepatoblastoma (32 cases, 16.5%).
  • Half of the fetuses and neonates with hepatoblastoma had abnormally elevated serum alpha-fetoprotein levels compared with 16 (14%) of 117 of those with hemangioma and 1 neonate with mesenchymal hamartoma.
  • There were 76 (65%) examples of solitary (unifocal) hemangiomas and 41 (35%) of multifocal (which included the entity diffuse hemangiomatosis) with 86% and 71% survival rates, respectively.
  • There was some relationship between histologic type and prognosis.
  • Fifteen of 32 hepatoblastoma patients received surgical resection with or without chemotherapy, resulting in 7 (47%) of 15 cures.
  • The 56 fetuses and 138 neonates with hepatic tumors (hemangioma, mesenchymal hamartoma, and hepatoblastoma) had survival rates of 75%, 64%, and 25%, respectively.
  • CONCLUSIONS: The study shows that clinical findings in fetuses and neonates with hepatic tumors are less well defined than in older children.
  • Some hepatic tumors have a better prognosis than others.
  • Neonates with focal (solitary) hepatic hemangiomas have the best outcome and fetuses with hepatoblastoma the worst.
  • Although infantile hemangioma undergoes spontaneous regression, it may be life threatening when congestive heart failure and/or consumptive coagulopathy occur.
  • Mesenchymal hamartoma is a benign lesion best treated by surgical resection, which usually results in cure.
  • Pre- or postoperative chemotherapy is reserved for those patients with unresectable tumors or metastatic disease.
  • Because of the danger of labor-induced rupture of the tumor and potentially fatal intraabdominal hemorrhage, cesarean delivery is recommended when a hepatic tumor is found on prenatal ultrasound.
  • [MeSH-major] Hamartoma / congenital. Hemangioma / congenital. Hepatoblastoma / congenital. Liver Neoplasms / congenital. Liver Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022426.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


17. Le Luyer B, Duquenoy A, Poinsot J, Boulloche J, Gaussin G, Le Roux P: [Use of interferon in a case of hepatic hemangioma]. Arch Pediatr; 2000 Nov;7(11):1201-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of interferon in a case of hepatic hemangioma].
  • [Transliterated title] Utilisation de l'interféron dans un cas d'hémangiome hépatique.
  • Hepatic hemangioendothelioma can have a fatal outcome.
  • After failure of classic therapies, and when surgery or arterial embolization are not possible, those benign tumours may benefit from interferon alpha treatment.
  • CASE REPORT: We report a case of a 14-month-old infant who presented with hepatic hemangiomatosis and cardiac failure.
  • The disease can neither be controlled by steroids nor by radiotherapy associated with digitalo-diuretic treatment.
  • CONCLUSION: Interferon alpha treatment helps to control cardiac failure and the course of hepatic hemangioma in childhood.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hemangioendothelioma / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Female. Humans. Infant. Treatment Outcome

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11109948.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


18. Granov AM, Tiutin LA, Tarazov PG, Granov DA: [Modern technologies of diagnosis and combined surgical treatment in liver tumors]. Vestn Ross Akad Med Nauk; 2003;(10):51-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern technologies of diagnosis and combined surgical treatment in liver tumors].
  • Modern technologies used at St. Petersburg Central Research Institute of Roentgenology and Radiotherapy of Russia's Ministry of Health in the diagnosis and treatment of malignant and benign liver cancers are surveyed in the paper.
  • Apart from routine examinations, like ultrasound scanning, computer tomography, MRT, angiography, the below new technologies were widely used: multi-stratum spiral computer tomography, special MRT techniques and positron-emission tomography.
  • The new methods enabled us to diagnose the tumor and its extension, to choose an optimal intervention technique, to make an objective assessment of the results and to correct the treatment strategy.
  • Preoperative embolization of the portal-vein branches in the damaged hepatic lobe and postoperative adjuvant local chemotherapy of the hepatic artery and portal vein belong to the new combined surgical treatment scheme.
  • The method of combined arterial-portal chemoembolization, used in unresectable malignant hepatic pathologies, extends the survival of patients by 3-5 times.
  • Ferromagnetic embolization presupposes the administration of ferromagnetic, through the arterial bed or direct puncture, into the tumor with a subsequent SHF-current treatment which brings about a selective tumor hyperthermia without heating the normal hepatic parenchyma.
  • Arterial embolization combined with local injection sclerotherapy in hemangiomas of the liver provides for a complete regeneration of benign tumors and can be regarded as a low-trauma alternative to liver resection.
  • The use of new methods of diagnosis and treatment expands the possibilities of surgical care for patients with hepatic neoplasms and essentially improves the treatment results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14598512.001).
  • [ISSN] 0869-6047
  • [Journal-full-title] Vestnik Rossiiskoi akademii meditsinskikh nauk
  • [ISO-abbreviation] Vestn. Akad. Med. Nauk SSSR
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


19. Wananukul S, Voramethkul W, Nuchprayoon I, Seksarn P: Diffuse Neonatal Hemangiomatosis: report of 5 cases. J Med Assoc Thai; 2006 Aug;89(8):1297-303
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diffuse Neonatal Hemangiomatosis (DNH) is a rare, life-threatening condition associated with a few to hundreds of small, cutaneous and visceral hemangiomas.
  • The authors reported 5 cases of DNH in which hepatic hemangioma were the most common visceral involvement.
  • Response to prednisolone in these cases was not good, one died and four required second line therapy.
  • [MeSH-major] Angiomatosis / diagnosis. Angiomatosis / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Hemangioma / diagnosis. Hemangioma / drug therapy. Liver Neoplasms / diagnosis. Liver Neoplasms / drug therapy. Prednisolone / therapeutic use. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Vinblastine / therapeutic use

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048444.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


20. Szymik-Kantorowicz S, Kobylarz K, Krysta M, Górecki W, Bysiek A, Celmer E, Dzierzega M: Interferon-alpha in the treatment of high-risk haemangiomas in infants. Eur J Pediatr Surg; 2005 Feb;15(1):11-6
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interferon-alpha in the treatment of high-risk haemangiomas in infants.
  • BACKGROUND: Haemangiomas are benign tumours that may occasionally compress vital structures, or cause consumptive coagulopathy and heart failure.
  • We describe our recent experience with interferon-alpha as a treatment modality for high-risk haemangiomas.
  • PATIENTS AND METHODS: Eight children with high-risk haemangiomas were treated with interferon-alpha, six of which had failed previous steroid therapy.
  • RESULT: Seven children responded to interferon therapy, one boy with a liver haemangioma died.
  • CONCLUSION: Interferon-alpha is an effective treatment modality for high-risk haemangiomas in children, especially in steroid-resistant patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Facial Neoplasms / drug therapy. Hemangioma / drug therapy. Interferon-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Pediatr Surg. 2007 Apr;17(2):147 [17503313.001]
  • (PMID = 15795821.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


21. Sylvestre VT, Dunton CJ: Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review. Horm Cancer; 2010 Apr;1(2):112-5
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent endometrial stromal sarcoma with letrozole: a case report and literature review.
  • She had a computed tomography that showed a pelvic mass, an enlarged right internal iliac lymph node, an atypical liver hemangioma, and a severe left hydronephrosis.
  • After 24 months of therapy, the patient remained free of disease.
  • Progestins function to decrease the effects of estrogen on target cells and have been used for primary therapy of endometrial stromal sarcomas.
  • Letrozole is a type 2 aromatase inhibitor that effectively reduces serum estrogen levels.
  • Letrozole has been described as treatment for endometrial stromal sarcoma.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Endometrial Neoplasms / drug therapy. Nitriles / therapeutic use. Sarcoma, Endometrial Stromal / drug therapy. Triazoles / therapeutic use
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Female. Humans. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Reprod Update. 1995 Jan;1(1):19-34 [9080204.001]
  • [Cites] Gynecol Oncol. 1987 Jan;26(1):87-97 [3792939.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):347-52 [17545798.001]
  • [Cites] Cancer. 2009 May 1;115(9):1867-74 [19241422.001]
  • [Cites] Drugs. 1998 Dec;56(6):1125-40 [9878997.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3477-80 [17972504.001]
  • [Cites] Surg Gynecol Obstet. 1965 Sep;121:531-7 [14332889.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Aug;20(6):433-47 [18499412.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1511-5 [9815951.001]
  • [Cites] Gynecol Oncol. 2003 Jul;90(1):170-6 [12821359.001]
  • [Cites] N Engl J Med. 1993 Aug 5;329(6):404-12 [8326975.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):104-8 [14631363.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):769-71 [15582003.001]
  • [Cites] Gynecol Oncol. 2006 Jun;101(3):464-9 [16368128.001]
  • [Cites] Obstet Gynecol. 1962 Jul;20:23-35 [13871981.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):384-8 [11531300.001]
  • [Cites] Am J Clin Oncol. 2008 Dec;31(6):595-605 [19060594.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Oct;5(10):1031-44 [15535424.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):173-4; author reply 174-5 [15963815.001]
  • [Cites] J Natl Cancer Inst. 1986 Mar;76(3):399-402 [3456457.001]
  • [Cites] Pathology. 2007 Feb;39(1):55-71 [17365823.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2431-42 [12802030.001]
  • [Cites] Med Oncol. 2003;20(1):87-93 [12665689.001]
  • (PMID = 21761354.001).
  • [ISSN] 1868-8500
  • [Journal-full-title] Hormones & cancer
  • [ISO-abbreviation] Horm Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  •  go-up   go-down


22. Hurvitz SA, Hurvitz CH, Sloninsky L, Sanford MC: Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. J Pediatr Hematol Oncol; 2000 Nov-Dec;22(6):527-32
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver.
  • A female neonate with diffuse hemangiomatosis and hepatic hemangiomas had cardiac insufficiency develop and had failure to thrive.
  • Twelve days after the second course of cyclophosphamide, her liver was significantly smaller.
  • She is now 6-years-old, well-developed, and has no signs of hepatomegaly, malnourishment, or heart failure.
  • Cyclophosphamide appears to be a safe, effective, and rapid treatment of life-threatening hemangiomas of infancy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cyclophosphamide / therapeutic use. Hemangioma / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Drug Administration Schedule. Failure to Thrive / etiology. Female. Heart Failure / etiology. Humans. Infant, Newborn. Magnetic Resonance Imaging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11132222.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  • [Number-of-references] 45
  •  go-up   go-down


23. Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ: Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther; 2009 Jul;8(7):1799-807
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
  • We tested atorvastatin as a therapy for (a) ethylnitrosourea (ENU)-enhanced renal cystadenoma and (b) spontaneous liver hemangioma in 129Sv/Jae Tsc2(+/-) mice.
  • All treatment groups were compared with mice of identical genotype and strain background that were fed control chow.
  • Pathologic analyses revealed a predominance of renal cystadenoma in ENU-treated and liver hemangioma in non-ENU-treated 129Sv/Jae Tsc2(+/-) mice.
  • In both cohorts, serum cholesterol levels and levels of phosphorylated S6 and GTP-RhoA in healthy tissue were significantly (>50%) reduced in atorvastatin-treated mice as compared with controls.
  • Following atorvastatin treatment, no significant reduction in tumor size, morphology, or phosphorylated S6 levels was observed for either ENU-associated renal cystadenoma or spontaneous liver hemangioma as compared with the untreated groups.
  • In conclusion, although the marked reduction in cholesterol levels indicates that atorvastatin was effective as an 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, it did not inhibit the growth of tumors that develop in these Tsc2(+/-) models, suggesting that it is unlikely to have benefit as a single-agent therapy for TSC-associated tumors.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2001 May 4;105(3):357-68 [11348592.001]
  • [Cites] Curr Cancer Drug Targets. 2005 Dec;5(8):579-94 [16375664.001]
  • [Cites] Hum Mol Genet. 2002 Mar 1;11(5):525-34 [11875047.001]
  • [Cites] J Biol Chem. 2002 Mar 22;277(12):10678-82 [11788600.001]
  • [Cites] J Biol Chem. 2002 Aug 23;277(34):30958-67 [12045200.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):648-57 [12172553.001]
  • [Cites] Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):593-613 [12616706.001]
  • [Cites] Curr Biol. 2003 Aug 5;13(15):1259-68 [12906785.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32493-6 [12842888.001]
  • [Cites] Trends Biochem Sci. 2004 Jan;29(1):32-8 [14729330.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3436-43 [15150095.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4188-94 [14976045.001]
  • [Cites] J Biol Chem. 2004 May 28;279(22):23114-22 [15039427.001]
  • [Cites] Cell Signal. 2004 Oct;16(10):1105-12 [15240005.001]
  • [Cites] Mol Cell Biol. 2004 Sep;24(18):7965-75 [15340059.001]
  • [Cites] N Engl J Med. 1988 Jul 7;319(1):24-33 [3288867.001]
  • [Cites] Nature. 1990 Feb 1;343(6257):425-30 [1967820.001]
  • [Cites] J Biol Chem. 1992 Oct 5;267(28):20033-8 [1400319.001]
  • [Cites] Cell. 1993 Dec 31;75(7):1305-15 [8269512.001]
  • [Cites] Annu Rev Biochem. 1996;65:241-69 [8811180.001]
  • [Cites] Tohoku J Exp Med. 1996 Oct;180(2):131-8 [9111762.001]
  • [Cites] Science. 1997 Aug 8;277(5327):805-8 [9242607.001]
  • [Cites] Breast Cancer Res Treat. 1998 Jul;50(1):83-93 [9802623.001]
  • [Cites] J Cell Sci. 1998 Dec 18;111 ( Pt 24):3633-43 [9819354.001]
  • [Cites] J Clin Invest. 1999 Sep;104(6):687-95 [10491404.001]
  • [Cites] Arthritis Rheum. 2004 Dec;50(12):4051-9 [15593180.001]
  • [Cites] J Cell Biol. 2004 Dec 20;167(6):1171-82 [15611338.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8648-55 [15623649.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Mar;42(3):213-27 [15578690.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Mar 15;171(6):606-15 [15591471.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] J Surg Res. 2005 Nov;129(1):52-6 [16087194.001]
  • [Cites] Endothelium. 2005 Sep-Dec;12(5-6):233-41 [16410222.001]
  • [Cites] Med Res Rev. 2006 Mar;26(2):160-80 [16329102.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):7370-7 [16849589.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5480-7 [17875778.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9878-86 [17942919.001]
  • [Cites] N Engl J Med. 2008 Jan 10;358(2):140-51 [18184959.001]
  • [Cites] Urology. 2008 Jan;71(1):118-22 [18242378.001]
  • [Cites] Transplantation. 2008 Feb 27;85(4):636-9 [18347544.001]
  • [Cites] Am J Med. 2008 Apr;121(4):302-9 [18374689.001]
  • [Cites] Liver Transpl. 2008 May;14(5):633-8 [18324656.001]
  • [Cites] Transplant Proc. 2008 Apr;40(3):711-3 [18454994.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33 [18463402.001]
  • [Cites] Am J Cardiol. 2008 Jun 1;101(11):1560-6 [18489933.001]
  • [Cites] J Am Coll Cardiol. 2008 May 27;51(21):2017-24 [18498954.001]
  • [Cites] Ann Pharmacother. 2008 Jul;42(7):1143-5 [18559956.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):308-17 [11832446.001]
  • (PMID = 19584242.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / K08 HL074113; United States / NHLBI NIH HHS / HL / K08 HL074113-03; United States / NCI NIH HHS / CA / P01 CA120964; United States / NHLBI NIH HHS / HL / K08 HL074113-05; United States / NHLBI NIH HHS / HL / HL074113-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heptanoic Acids; 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Pyrroles; 0 / Tumor Suppressor Proteins; 48A5M73Z4Q / Atorvastatin Calcium; 4JG2LF96VF / tuberous sclerosis complex 2 protein; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ NIHMS119618; NLM/ PMC2712945
  •  go-up   go-down


24. Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J, Ohanessian G, Léauté-Labrèze C, Labenne M, Vabres P, Rössler J, Bodemer C: Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr; 2010 Aug;157(2):340-2
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.
  • We report the rapid and dramatic efficacy of propranolol in 8 infants with infantile hepatic hemangiomas.
  • The degree of response varied from a significant improvement to a complete resolution of hepatic lesions.
  • No side-effects of the drug were noted.
  • [MeSH-major] Hemangioma / drug therapy. Liver Neoplasms / drug therapy. Propranolol / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Female. Heart Failure / prevention & control. Humans. Infant. Male. Treatment Outcome. Vasodilator Agents / therapeutic use

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20488455.001).
  • [ISSN] 1097-6833
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Vasodilator Agents; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


25. Enjolras O, Brevière GM, Roger G, Tovi M, Pellegrino B, Varotti E, Soupre V, Picard A, Leverger G: [Vincristine treatment for function- and life-threatening infantile hemangioma]. Arch Pediatr; 2004 Feb;11(2):99-107
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vincristine treatment for function- and life-threatening infantile hemangioma].
  • [Transliterated title] Traitement par vincristine des hémangiomes graves du nourrisson.
  • AIM: To evaluate the efficacy of vincristine treatment for function- and life-threatening hemangiomas.
  • PATIENTS AND METHOD: Nine infants, eight girls and one boy, received vincristine treatment (VCR) for endangering hemangiomas.
  • In six cases, the hemangiomas involved head and neck in a segmental unilateral or bilateral distribution (3/6 also had laryngeal and 2/6 tracheal location causing respiratory distress, 5/6 had eyelid and orbital involvement); one infant had disseminated neonatal hemangiomatosis (skin, liver, kidney); two infants had liver hemangiomas with cardiac failure.
  • VCR was prescribed after failure of high-dosage corticosteroid treatment in six, and of both corticosteroids and interferon alpha 2b (5 months) in one; two infants received VCR as first line treatment.
  • The nine infants received from 5 to 25 injections (average: 16), for a length of treatment of 1.5-8 months (average: 5.5 months).
  • In seven patients a clear clinical response was observed at the end of the first month of treatment, while a slow protracted response was noted in two.
  • DISCUSSION: Corticosteroid treatment, although a worldwide recognized treatment of problematic hemangiomas, cannot always control the growth of alarming hemangiomas.
  • Interferon alpha 2a and 2b have proven a 90% effectiveness: treatment for cortico-resistant, function- and life-threatening, hemangiomas.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Hemangioma / drug therapy. Skin Neoplasms / drug therapy. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14761730.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  •  go-up   go-down


26. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N: Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol; 2010 Mar-Apr;27(2):195-6
Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol.
  • A 27-day-old male infant with diffuse hemangiomatosis of the skin and liver was treated with oral propranolol at a dosage of 2 mg/kg per day.
  • Five months later skin and liver hemangiomas regressed almost completely.
  • Although the risk appears small, increased vigilance for hypoglycemia in children on chronic propranolol treatment who have decreased caloric intake for any reason seems prudent.
  • [MeSH-major] Hemangioma / drug therapy. Hypoglycemia / chemically induced. Liver Neoplasms / drug therapy. Propranolol / adverse effects. Propranolol / therapeutic use
  • [MeSH-minor] Energy Intake. Humans. Infant, Newborn. Ketone Bodies / blood. Magnetic Resonance Imaging. Male. Skin Neoplasms / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20537072.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ketone Bodies; 9Y8NXQ24VQ / Propranolol
  •  go-up   go-down


27. Vlahovic A, Simic R, Djokic D, Ceran C: Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report. J Pediatr Hematol Oncol; 2009 Nov;31(11):858-60
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse neonatal hemangiomatosis treatment with cyclophosphamide: a case report.
  • There were 63 cutaneous hemangiomas over the scalp, face, trunk, and extremities.
  • Computed tomography scan revealed the presence of hemangiomas in the liver and kidneys; laryngobronchoscopy identified the presence of hemangioma in tracheobronchial tree.
  • Treatment with corticosteroids, in dose of 3 mg/kg/d intravenously, was initiated.
  • Each course consisted of 10 mg/kg/d of cyclophosphamide and 10 mg/kg/d of mesna for 4 consecutive days.
  • After 4 cycles of cyclophosphamide, the liver was notably decreased in size and the cardiac failure was resolved.
  • Magnetic resonance imaging of the abdomen revealed the marked decrease in size of the liver hemangioma.
  • After 3 years of follow-up the child is well developed, fully recovered, without cardiologic or respiratory problems.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Hemangioma / drug therapy. Hemangioma / pathology. Mesna / administration & dosage. Protective Agents / administration & dosage

  • Genetic Alliance. consumer health - Diffuse Neonatal Hemangiomatosis.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19829152.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Protective Agents; 8N3DW7272P / Cyclophosphamide; NR7O1405Q9 / Mesna
  •  go-up   go-down


28. Rasmussen A, Kvist N, Kirkegaard P, Rechnitzer C: [Surgical treatment of children with hepatic tumours]. Ugeskr Laeger; 2008 Apr 14;170(16):1366-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of children with hepatic tumours].
  • [Transliterated title] Kirurgisk behandling af levertumorer hos børn.
  • INTRODUCTION: In this paper we review the results of surgical treatment of children with hepatic tumours.
  • MATERIALS AND METHODS: The study comprises 33 children who have undergone lever resection or liver transplantation since 1990.
  • 26 patients had hepatoblastoma, 3 had hepatocellular carcinoma, 2 had rhabdomyosarcoma, 1 had a mesenchymal tumour, and 1 had a giant haemangioma.
  • RESULTS: Because of the number of patients, we only analyzed the results of the treatment in the hepatoblastoma group.
  • The survival was the same after resection (77.3%) and liver transplantation (75%).
  • There was no difference in survival dependent on the type of resection, and there was no impact of the extension of tumour growth at the time of diagnosis.
  • CONCLUSION: The combination of neoadjuvant chemotherapy followed by liver resection or liver transplantation is the treatment of choice in all children with hepatoblastoma.
  • Since 2000, very effective chemotherapy has downstaged all referred patients, so subsequent liver resection have been possible.
  • [MeSH-major] Hepatoblastoma / surgery. Liver Neoplasms / surgery
  • [MeSH-minor] Child. Hepatectomy. Humans. Liver Transplantation. Neoadjuvant Therapy. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433603.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


29. Sampol Bas C, Peña Viloria C: [Uptake of 123I-MIBG in a hepatic hemangioma in the scintigraphic study of an adrenal gland lesion]. Rev Esp Med Nucl; 2005 May-Jun;24(3):191-4
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uptake of 123I-MIBG in a hepatic hemangioma in the scintigraphic study of an adrenal gland lesion].
  • [Transliterated title] Captación de 123I-MIBG en un hemangioma hepático en el estudio gammagráfico de una lesión suprarrenal.
  • MRI confirmed the presence of a mass in the left adrenal gland suggestive of an adenoma and found a lesion in the right hepatic area at the level of the previously seen MIBG image.
  • This lesion was labelled as a hemangioma and would explain the findings of the isotopic study with MIBG.
  • The increased catecholamine serum and urine levels were due to drug interactions.
  • [MeSH-major] 3-Iodobenzylguanidine. Adrenal Glands / radiography. Diagnostic Errors. Hemangioma / radionuclide imaging. Iodine Radioisotopes. Liver Neoplasms / radionuclide imaging
  • [MeSH-minor] Adenoma / diagnosis. Adrenal Gland Neoplasms / diagnosis. Adrenergic Uptake Inhibitors / adverse effects. Adrenergic Uptake Inhibitors / pharmacology. Adrenergic Uptake Inhibitors / therapeutic use. Antidepressive Agents / adverse effects. Antidepressive Agents / pharmacology. Antidepressive Agents / therapeutic use. Antipsychotic Agents / adverse effects. Antipsychotic Agents / pharmacology. Antipsychotic Agents / therapeutic use. Catecholamines / blood. Diagnosis, Differential. Drug Interactions. False Positive Reactions. Female. Fibula / injuries. Fibula / radiography. Fractures, Bone / complications. Fractures, Bone / radiography. Humans. Incidental Findings. Magnetic Resonance Imaging. Middle Aged. Pheochromocytoma / diagnosis. Psychotic Disorders / complications. Psychotic Disorders / drug therapy. Tibial Fractures / complications. Tibial Fractures / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15847786.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Adrenergic Uptake Inhibitors; 0 / Antidepressive Agents; 0 / Antipsychotic Agents; 0 / Catecholamines; 0 / Iodine Radioisotopes; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


30. Nord KM, Kandel J, Lefkowitch JH, Lobritto SJ, Morel KD, North PE, Garzon MC: Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature. Pediatrics; 2006 Sep;118(3):e907-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature.
  • Multiple cutaneous hemangiomas can be associated with internal hemangiomas, with the liver being the most common site.
  • Here we report a case of a premature female neonate who presented with cardiac failure at birth and had typical-appearing infantile hemangiomas on the skin in association with vascular lesions in the liver.
  • Her clinical presentation was felt to be consistent with cutaneous and hepatic infantile hemangiomas.
  • After failure to respond to systemic steroids and chemotherapy, she underwent liver transplantation.
  • Histopathologic evaluation of the liver revealed a diagnosis of type 2 infantile hepatic hemangioendothelioma (regarded as synonymous with angiosarcoma) rather than benign infantile hemangioma of the liver.
  • Subsequent skin biopsies confirmed that her multiple cutaneous lesions were infantile hemangiomas and not metastatic angiosarcoma.
  • We report this case and a review of the literature on pediatric angiosarcoma of the liver associated with cutaneous infantile hemangiomas.
  • [MeSH-major] Hemangioma / pathology. Hemangiosarcoma / pathology. Liver Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Female. Heart Defects, Congenital. Humans. Infant, Newborn. Liver Transplantation

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatrics. 2007 Jun;119(6):1271
  • (PMID = 16880251.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


31. Koniaris LG, Seibel JA, Geschwind JF, Sitzmann JV: Can ethanol therapies injure the bile ducts? Hepatogastroenterology; 2003 Jan-Feb;50(49):69-72
Hazardous Substances Data Bank. ETHANOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can ethanol therapies injure the bile ducts?
  • Administration of ethanol, whether applied directly to tissue or via an intra-arterial route, has been widely used to treat a variety of hepatic disorders, most importantly hepatocellular carcinoma.
  • Animal studies, however, have demonstrated that intravascular hepatic ethanol therapy causes significant bile duct injury, and therefore, many centers have used intravascular ethanol applications with caution.
  • A case of extensive bile duct injury in a 35-year-old female with a symptomatic hepatic hemangioma treated with ethanol embolization is presented.
  • Although a seemingly rare complication, the possibility of bile duct injury should be considered prior to planned ethanol liver treatment, and a high index of suspicion should be maintained should signs of hepatic dysfunction subsequently arise.
  • [MeSH-major] Bile Ducts / drug effects. Bile Ducts / injuries. Embolization, Therapeutic / adverse effects. Ethanol / adverse effects. Ethanol / therapeutic use. Hemangioma / therapy. Liver Neoplasms / therapy. Solvents / adverse effects. Solvents / therapeutic use

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12629993.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Solvents; 3K9958V90M / Ethanol
  •  go-up   go-down


32. Schiavetti A, De Pasquale MD, Di Salvo S, Ventriglia F, Clerico A: Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report. Pediatr Hematol Oncol; 2003 Mar;20(2):161-5
Hazardous Substances Data Bank. FUROSEMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recombinant interferon alfa 2a in hepatic hemangiomatosis with congestive heart failure: a case report.
  • Four cutaneous angiomas were noted.
  • Instrumental examinations revealed congestive heart failure and multiple focal lesions in the liver with typical features of hemangiomas.
  • The therapy with subcutaneous interferon-alfa-2a (IFN-alpha) was administered for 12 months with progressive regression of cutaneous hemangiomas, liver lesions, and cardiological alterations.
  • IFN-alpha therapy was effective without any significant adverse effects.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Heart Failure / etiology. Hemangioma / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Abdominal Neoplasms / congenital. Abdominal Neoplasms / drug therapy. Digitalis Glycosides / therapeutic use. Diuretics / therapeutic use. Dyspnea / etiology. Female. Furosemide / therapeutic use. Head and Neck Neoplasms / congenital. Head and Neck Neoplasms / drug therapy. Heart Septal Defects, Atrial / complications. Heel. Hemangioma, Capillary / congenital. Hemangioma, Capillary / drug therapy. Hemangioma, Cavernous / congenital. Hemangioma, Cavernous / drug therapy. Hepatomegaly / etiology. Humans. Infant. Knee. Neoplasms, Multiple Primary / congenital. Neoplasms, Multiple Primary / drug therapy. Recombinant Proteins. Remission Induction

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Heart Failure.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12554528.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Digitalis Glycosides; 0 / Diuretics; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


33. Sarialioglu F, Erbay A, Demir S: Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy. Pediatr Blood Cancer; 2010 Dec 15;55(7):1433-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Response of infantile hepatic hemangioma to propranolol resistant to high-dose methylprednisolone and interferon-α therapy.
  • [MeSH-major] Drug Resistance, Neoplasm. Hemangioendothelioma / drug therapy. Interferon-alpha / administration & dosage. Liver Neoplasms / drug therapy. Methylprednisolone / administration & dosage. Propranolol / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Infant. Male

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. PROPRANOLOL HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981697.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 9Y8NXQ24VQ / Propranolol; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


34. Schmitz R, Heinig J, Klockenbusch W, Kiesel L, Steinhard J: Antenatal diagnosis of a giant fetal hepatic hemangioma and treatment with maternal corticosteroid. Ultraschall Med; 2009 Jun;30(3):223-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antenatal diagnosis of a giant fetal hepatic hemangioma and treatment with maternal corticosteroid.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Dexamethasone / administration & dosage. Hemangioendothelioma / congenital. Hemangioendothelioma / drug therapy. Image Processing, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Liver Neoplasms / congenital. Liver Neoplasms / drug therapy. Ultrasonography, Prenatal / methods
  • [MeSH-minor] Abnormalities, Multiple / ultrasonography. Administration, Oral. Cesarean Section. Embolization, Therapeutic. Female. Follow-Up Studies. Hemodynamics / drug effects. Hemodynamics / physiology. Humans. Infant, Newborn. Male. Pregnancy. Syndrome. Ultrasonography, Doppler. Umbilical Arteries / ultrasonography

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ultraschall Med. 2009 Jun;30(3):226
  • (PMID = 19507116.001).
  • [ISSN] 1438-8782
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] eng; ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down






Advertisement